Marker Therapeutics Inc
NASDAQ:MRKR

Watchlist Manager
Marker Therapeutics Inc Logo
Marker Therapeutics Inc
NASDAQ:MRKR
Watchlist
Price: 3.8 USD 1.88% Market Closed
Market Cap: 33.9m USD
Have any thoughts about
Marker Therapeutics Inc?
Write Note

Marker Therapeutics Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Marker Therapeutics Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Marker Therapeutics Inc
NASDAQ:MRKR
Total Liabilities
$3.5m
CAGR 3-Years
-44%
CAGR 5-Years
0%
CAGR 10-Years
10%
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%
No Stocks Found

Marker Therapeutics Inc
Glance View

Market Cap
33.8m USD
Industry
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

MRKR Intrinsic Value
3.84 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Marker Therapeutics Inc's Total Liabilities?
Total Liabilities
3.5m USD

Based on the financial report for Sep 30, 2024, Marker Therapeutics Inc's Total Liabilities amounts to 3.5m USD.

What is Marker Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
10%

Over the last year, the Total Liabilities growth was 24%. The average annual Total Liabilities growth rates for Marker Therapeutics Inc have been -44% over the past three years , and 10% over the past ten years .

Back to Top